ASND — Ascendis Pharma A/S Share News
0.000.00%
Last trade - 00:00- $15.00bn
- $14.59bn
- €720.13m
Ascendis Pharma A/S expected to post a loss of €2.59 a share - Earnings Preview
Ascendis Pharma A/S expected to post a loss of €2.59 a share - Earnings Preview
Ascendis Pharma jumps as FDA does not seek new trial for hormone disorder therapy
FDA declines approval for Ascendis Pharma's hormone disorder treatment
Ascendis Pharma A/S reports results for the quarter ended in March - Earnings Summary
Ascendis Pharma A/S expected to post a loss of €2.66 a share - Earnings Preview
Ascendis Pharma A/S reports results for the quarter ended in December - Earnings Summary
Ascendis Pharma A/S expected to post a loss of €2.56 a share - Earnings Preview
SVB sees blockbuster revenue from Ascendis Pharma's endocrine disorder therapy
Ascendis falls as analysts say dwarfism drug less effective vs rival BioMarin's
BioMarin rises as analysts say rival Ascendis' dwarfism drug less effective
U.S. RESEARCH ROUNDUP-ACI Worldwide, Kaman, Sinclair Broadcast Group
Ascendis Pharma A/S reports results for the quarter ended in September - Earnings Summary
Ascendis Pharma A/S expected to post a loss of €2.49 a share - Earnings Preview
Brief: FDA Accepts For Priority Review Ascendis Pharma's NDA For TransCon PTH In Adult Patients With Hypoparathyroidism
Ascendis Pharma A/S reports results for the quarter ended in June - Earnings Summary
Ascendis Pharma A/S expected to post a loss of €2.13 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Avalara, Citigroup, Rayonier Advanced Materials
U.S. RESEARCH ROUNDUP-Avalara, Citigroup, Rayonier Advanced Materials